Cara CDRS (Conduction Disturbance Risk Score) 1.0
Launched by CARA MEDICAL LTD · Dec 19, 2022
Trial Information
Current as of January 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Cara CDRS 1.0 clinical trial is studying a new way to assess the risk of heart rhythm problems in patients undergoing a procedure called Transcatheter Aortic Valve Replacement (TAVR). These heart rhythm issues can sometimes lead to the need for a pacemaker or cause other complications, which may increase the chances of further health problems. In this trial, researchers will collect heart monitoring data (ECG) from 600 patients before, during, and after their TAVR procedure to see how well the Cara Conduction Disturbance Risk Score (CDRS) can predict these risks.
To be eligible for the study, participants must be at least 18 years old, meet the requirements for having a TAVR procedure, and agree to follow-up evaluations. They should not already have devices like pacemakers or have other health issues that would prevent them from safely undergoing the TAVR procedure. Participants in the trial will not receive any special treatments; instead, their heart data will be analyzed after the procedure to help improve understanding of heart rhythm risks associated with TAVR. This study aims to gather important information that could help doctors better manage patients' care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must meet be ≥ 18 years of age.
- • Must meet indications for TAVR using approved devices
- • Provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- • Willing to comply with specified follow-up evaluations.
- • Must meet the legal minimum age to provide Informed Consent based on local regulatory requirements.
- Exclusion Criteria:
- • Any implanted device or an indication for treatment with a rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy (CRT), or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) at baseline.
- • Any contraindication to the TAVR procedure according to the instructions for use.
- • Less than the legal age of consent, legally incompetent, or otherwise vulnerable.
- • Planned treatment with any other investigational device, drug, or procedure (excluding registries) during the study period.
Trial Officials
Helena Grinberg-Rashi, PhD
Study Chair
helenag@k2-medicalltd.com
About Cara Medical Ltd
Cara Medical Ltd. is a dedicated clinical trial sponsor focused on advancing innovative therapies to improve patient outcomes in the field of healthcare. With a commitment to rigorous scientific research and ethical standards, Cara Medical Ltd. collaborates with medical professionals and regulatory bodies to design, implement, and oversee clinical trials that evaluate the safety and efficacy of novel treatments. The company leverages its expertise in clinical development to facilitate the timely delivery of groundbreaking solutions to the market, ultimately aiming to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Milano, , Italy
Québec, , Canada
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials